Losing my mind. Let's go!

I've always been a fan of what the Allen Institute is doing. New in Nature: OpenScholar, an 8B RAG model for scientific literature, outperforms GPT-4o by 6% on correctness. Experts preferred its answers over human-written ones 51%-70 of the time. www.nature.com/articles/s41... 1/3 🧵

In a new Science study, researchers introduce DrugCLIP, a contrastive learning framework that virtually screens small molecules and protein pockets, analyzing protein-ligand interactions 10 million times faster than most standard molecular docking approaches. https://scim.ag/45FfSj2

Delighted to have our work on 🧬 resilience to 🩸cancer led by @g-agarwal.bsky.social & amazing collaborators, including @kharaslab.bsky.social, published in @science.org: www.science.org/doi/10.1126/... 🧵

I’ve always preferred reference hiring over interviews.

Come check out our poster for an ongoing trial of ASTX727 +/- Iadademstat in accelerated/blast-phase MPNs #ASH25

Leadership simplified: Hire good people. Give them the tools to succeed. Provide them the security to take calculated risks. Get out of their way. Let go of over-controlling. Support, don't thwart. Cultivate intrinsic motivation. Trust them to do their job.

Team culture does not form during meetings or scheduled activity. It forms during the in between moments. The cool down conversations, the shared anxiety while awaiting a race, the adventures once the performance is complete and you have got hours to kill in a different city.

BEST BIG CITY IN THE US 9 YEARS IN A ROW. While critics try to paint Chicago as something to fear, the rest of the world knows the truth — this is the best big city in America.

Why do complex traits differ in their genetic architecture? In our new PLOS Biology paper, we will try to convince you that two simple scaling laws drive differences in the number, effect sizes and frequencies of causal variants affecting complex traits. Thread: journals.plos.org/plosbiology/...

Finally, someone has solved a real problem with AI! No more having to take a paper in the format for a journal that rejected you, and reformat it for a new journal. Well done!! formatmypaper.com

Amplifying one of our neighboring programs - great place to train and GR is a great place to live

"A 2019 report from the US NASEM report on mentorship in science notes that researchers who invest time in their students tend to lead more-productive, more-collaborative groups and attract stronger future students than those who do not." www.nature.com/articles/d41...

Awesome application of genomics + cancer bio

Good news for @alice.soragnilab.com, SFPM, and rare disease models. Bad news for mouse cancer enthusiasts (humans are unreliable models of mouse disease).

In this edition of #ScienceAdviser, Science Immunology Senior Editor @cnfogg.bsky.social talks about how her love of running led her to be the subject of science—rather than the editor of it. Plus more of the best from @science.org and science: www.science.org/content/arti... 🧪

Different results than those found in preserved samples www.nature.com/articles/s41...

New online! Tracing the evolution of sequencing into the era of genomic medicine

In the ENHANCE-2 study, Magro/Aza did not improve OS of patients with TP53-mutated AML. buff.ly/8DeMMxH #hemesky

DRAGEN rapidly identifies diverse types of genetic variants go.nature.com/4eXQRT1 rdcu.be/ezphs

In a recently published article in NEJM, Ari Rosenberg, MD, and Everett Vokes, MD, discuss the promise and complexities of the KEYNOTE-689 trial, which shows event-free survival benefits from pembrolizumab in curative-intent settings. @arirosenbergmd.bsky.social pubmed.ncbi.nlm.nih.gov/40532147/

From today, all new submissions to Nature that are published will be accompanied by referees’ reports and author responses — to illuminate the process of producing rigorous science https://go.nature.com/4kIRR01

+1

Guidelines for writing: • Just get started—no writer's block; only getting started block • Write for clarity first • Write for elegance second • Delete excess words • Don't write and edit at same time • OK for first drafts to stink • Read your work aloud • Get good sleep

In a study on world class performers, those who made it world class: -Had more multisport than specialized practice -Started their main sport later -Accumulated less practice -Initially progressed slower than national class peers

🚨 New research finds women with BRCA1/2 mutations who received textured breast implants after mastectomy face a 16x higher risk of developing BIA-ALCL, a rare lymphoma. Study highlights need for awareness years after surgery. 🔗 https://bit.ly/404WEk1 @bloodjournals.hematology.org

How awesome is this?! JAMA Network Open @jamanetworkopen.com - an open access journal in the JAMA Network - is now on BlueSky! #MedSky

CrossFilt: A Cross-species Filtering Tool that Eliminates Alignment Bias in Comparative Genomics Studies www.biorxiv.org/content/10.1... 🧬🖥️🧪 github.com/kennethabarr...

Elon/DJT break up is the biggest split since WHO/ICC

Classic. @greenwell.bsky.social, your media training is working because I just saved your audiobook to my Spotify library. Keep fighting the good fight, this is an important issue.

Out today in @pnas.org! www.pnas.org/doi/10.1073/...

💍 The Gollum Effect: possessive behaviours, attempts to undermine others, and efforts to restrict access to data, resources or opportunities https://go.nature.com/4mxAJvG

Key rules to achieve sustainable success: 1. Consistency trumps perfection. 2. Be a minimalist to be a maximalist. 3. Have a quiet ego. 4. Focus on the process, not results. 5. Establish a secure but flexible identity. 6. Stress + Rest = Growth

Was discussing a recent case with a colleague when the utility of the day 14 marrow in our patients undergoing intensive induction for AML was discussed. Prompted a return to the "old" literature on this topic, much of which was written by Eli Estey (and @drchrishourigan.bsky.social).

Vicar of Christ

Classic lecture from Michael Joyner: "Is reductionism killing biomedical research?" youtu.be/dG8lszogw_E?... Nearly a decade on, it has aged well

We've worked on eQTLs and CRISPR for 10+ years now, and 4 years ago I hypothesized about their orthogonal strengths and weaknesses, for a review paper with @dgmacarthur.bsky.social. It’s exciting to finally have enough empirical data for a systematic analysis. www.science.org/doi/10.1126/...

1/ 🧬 A Hitchhiker’s Guide to Long-Read Genomic Analysis is out now! This mini-review walks through the latest advances in long-read DNA sequencing — from assemblies to variant calling to epigenetics. Link 🔗 genome.cshlp.org/content/35/4... 🧵👇

Probably a canary in a coal mine

Fact check: True.

From the #StemCellEvidence Alert: Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations by Baranwal et al. www.stemcellevidence.com/alerts/artic... #MedSky

Happy to have had a chat about some of our recent work in inherited hematological diseases and pregnancy loss published as a CAHLN Research Pulse podcast. Team effort. @SAPathology @CCB_Research @UniversitySA @SAHealth www.buzzsprout.com/1982738/epis...

Catching up on recent presentations in the HHM space - Dr. Tawana did a superb job summarizing recent updates in the field. Worth a listen! youtu.be/XGHbvMhFtH0?...

"The Rise of Jess McClain" Fantastic video about the top American finisher on the women's side at the Boston Marathon: youtu.be/LU3vBjUdY5M?...

What do you do if you have a patient with a low Absolute Neutrophil Count (ANC)? 🤔 Follow these steps to learn how to respond appropriately 👇 Download the ASH Neutropenia Navigator to learn more: www.hematology.org/e... #DuffyNull #DANC #ASHEducation #HemeSky #MedSky @ash.edu.hematology.org

7+7 continues to show encouraging results www.nature.com/articles/s41...

Induced pluripotent stem cells are being tested to treat blindness, paralysis, Parkinson’s disease and more. Approvals might be around the corner https://go.nature.com/42xdB7d

MAP Kinase pathway strikes again

In Brief: US FDA approves the first RNAi drug for treating heart failure caused by amyloidosis. Alnylam gets the nod for #Amvuttra (vutrisiran) to treat transthyretin amyloid cardiomyopathy caused by sporadic or hereditary ATTR, expanding the drug’s label www.nature.com/articles/s41... rdcu.be/ehRIa